NCT06216171 Adaptive Radiotherapy in Head and Neck Tumor Patients
| NCT ID | NCT06216171 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Essen |
| Condition | Head and Neck Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-01-25 |
| Primary Completion | 2025-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-01-25 with a primary completion date of 2025-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with radiochemotherapy with curative intent. If the field-set UP margins are broad, the consequence may be that quality of life is impaired. The study group of Nutting et al. (2023) investigated this year whether dysphagia-optimized intensity-modulated radiotherapy can reduce the radiation dose to structures associated with dysphagia and aspiration and improve swallowing function compared to standard IMRT (Nutting C, Finneran L, Roe J, Petkar I, Rooney K, Hall E; DARS Triallist Group. Dysphagia-optimized intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer - Authors' reply. Lancet Oncol. 2023 Oct;24(10):e398. doi: 10.1016/S1470-2045(23)00457-6. PMID: 37797636.) The study group concluded that the results suggest that dysphagia-optimized IMRT improves patient-reported swallowing function compared to standard IMRT. DO-IMRT should be considered the new standard of care for patients receiving radiotherapy for pharyngeal cancer, and ART could further improve outcomes.
Eligibility Criteria
Inclusion Criteria: ECOG 0/1 No prior cancer treatment Exclusion Criteria: ECOG 2-4 Prior cancer treatment
Frequently Asked Questions
Who can join the NCT06216171 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06216171 currently recruiting?
Yes, NCT06216171 is actively recruiting participants. Visit ClinicalTrials.gov or contact University Hospital, Essen to inquire about joining.
Where is the NCT06216171 trial being conducted?
This trial is being conducted at Essen, Germany.
Who is sponsoring the NCT06216171 clinical trial?
NCT06216171 is sponsored by University Hospital, Essen. The trial plans to enroll 30 participants.